Danaher today reported a 7 percent year-over-year increase in its third quarter revenues with its diagnostic revenues up 3 percent.

Agena Biosciences and DaRui Biotechnology announced today that Agena's MassArray system has been cleared by the China Food and Drug Administration.

An estimated 100 million-plus people, roughly one-third of the U.S. population, will have had their DNA analyzed using an at-home genetic test kit by 2021.

When it comes to in vitro diagnostic (IVD) technologies, medical device and diagnostic companies have been chomping at the bit to produce the next big innovation.

CARLSBAD, MA, UNITED STATES - Oct 17, 2018 - Marking a milestone in bringing its Oncomine Dx Target Test to Europe

Bacterial or viral infection, that is the question. Haifa-Israel based MeMed Diagnostics is developing a point-of-care platform and immune-based test that will one day be able to provide answers.

Patients living with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), or multiple sclerosis must see their health practitioners frequently to check the progression of their conditions and their responses to therapies.

BGI has analyzed the world’s largest set of genome data from pregnant women, a total of 141,431 expectant mothers from across China.

After setting its sights on a $100 million IPO, CAR-T player Allogene Therapeutics has nearly tripled that, pricing the deal at the high end of the range and raising $288 million.

It's hard to believe it's been a full year since Abbott closed its acquisition of Alere, considering what a contentious deal it was and how hard Abbott fought last year to get out of it.

Thermo Fisher Scientific said recently that its third quarter revenues grew 16 percent, driven by growth across its four business segments.

Recently, CEC and WuXi AppTec announced the establishment of a joint venture company, Zhongdian Yaoming, to jointly cultivate the health care big data industry.

Illumina reported recently that its revenues for the third quarter grew 20 percent year over year, driven by growth across its sequencing and microarray products.

NeoGenomics recently announced a definitive agreement to acquire clinical oncology laboratory Genoptix for $125 million in cash and 1 million shares of NeoGenomics' stock.

GeneWiz, Nashville Biosciences Collaborate to Combine NGS Services, Biobank DNA Samples